ProfileGDS5678 / 1432314_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 17% 17% 17% 16% 20% 17% 16% 16% 17% 17% 17% 17% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4267916
GSM967853U87-EV human glioblastoma xenograft - Control 22.4086617
GSM967854U87-EV human glioblastoma xenograft - Control 32.4129917
GSM967855U87-EV human glioblastoma xenograft - Control 42.3697917
GSM967856U87-EV human glioblastoma xenograft - Control 52.3491916
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5345420
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4347517
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3823516
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.37716
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4002117
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3960617
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3834517
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4022517
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3990717